tbuckley/cabot-search huggingface dataset:
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
Authors: T. Yoshino, D. Arnold, H. Taniguchi, G. Pentheroudakis, K. Yamazaki, R.-H. Xu, T.W. Kim, F. Ismail, I.B. Tan, K.-H. Yeh, A. Grothey, S. Zhang, J.B. Ahn, M.Y. Mastura, D. Chong, L.-T. Chen, S. Kopetz, T. Eguchi-Nakajima, H. Ebi, A. Ohtsu, A. Cervantes, K. Muro, J. Tabernero, H. Minami, F. Ciardiello, J.-Y. Douillard
Journal: Annals of Oncology (2017)

The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account the ethnic differences relating to the toxicity as well as other aspects of certain systemic treatments in patients of Asian ethnicity. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China (Chinese Society of Clinical Oncology), Korea (Korean Association for Clinical Oncology), Malaysia (Malaysian Oncological Society), Singapore (Singapore Society of Oncology) and Taiwan (Taiwan Oncology Society). The voting was based on scientific evidence and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.
Challenges in obstructive sleep apnoea
Authors: Walter T McNicholas, Claudio L Bassetti, Luigi Ferini-Strambi, Jean Louis Pépin, Dirk Pevernagie, Johan Verbraecken, Winfried Randerath, Walter T McNicholas, Claudio L Bassetti, Luigi Ferini-Strambi, Jean Louis Pépin, Dirk Pevernagie, Johan Verbraecken, Maria R Bonsignore, Ramon Farre, Ludger Grote, Jan Hedner, Malcolm Kohler, Miguel A Martinez-Garcia, Stefan Mihaicuta, Josep Montserrat, Fabio Pizza, Olli Polo, Renata L Riha, Silke Ryan, Winfried Randerath
Journal: The Lancet Respiratory Medicine (2018)
Hierarchical Active Inference: A Theory of Motivated Control
Authors: Giovanni Pezzulo, Francesco Rigoli, Karl J. Friston
Journal: Trends in Cognitive Sciences (2018)

Motivated control refers to the coordination of behaviour to achieve affectively valenced outcomes or goals. The study of motivated control traditionally assumes a distinction between control and motivational processes, which map to distinct (dorsolateral versus ventromedial) brain systems. However, the respective roles and interactions between these processes remain controversial. We offer a novel perspective that casts control and motivational processes as complementary aspects - goal propagation and prioritization, respectively - of active inference and hierarchical goal processing under deep generative models. We propose that the control hierarchy propagates prior preferences or goals, but their precision is informed by the motivational context, inferred at different levels of the motivational hierarchy. The ensuing integration of control and motivational processes underwrites action and policy selection and, ultimately, motivated behaviour, by enabling deep inference to prioritize goals in a context-sensitive way.
State Restrictions of e-Cigarette Use Has Slowed
Authors: Rita Rubin
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Timing of surgical site infection and pulmonary complications after laparotomy
Authors: Ossian Gundel, Sofie Kirchhoff Gundersen, Rikke Maria Dahl, Lars Nannestad Jørgensen, Lars S Rasmussen, Jørn Wetterslev, Ditte Sæbye, Christian S Meyhoff
Journal: International Journal of Surgery (2018)
Ulcerated Nodule of the Fingernail
Authors: Shari R. Lipner
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Descriptive Analysis of Diagnostic Methods In Betalactam Hypersensitivity in our Allergy Unit
Authors: Esther Barrionuevo, Natalia I. Pérez Sánchez, Francisca Gomez, María Salas, Maria Auxiliadora Guerrero, Dolores Ruiz, Angela Martin-Serrano Ortiz, Maria Jose Torres Jaén
Journal: Journal of Allergy and Clinical Immunology (2018)
Fever in the returning traveller
Authors: Doug Fink, Robert Serafino Wani, Victoria Johnston
Journal: BMJ (2018)

### What you need to know ### Sources and selection criteria We searched the Medline database (1994–2017) using the terms "fever," "travel," and "travel medicine." The search was limited to English language articles. Given the absence of randomised controlled trials in this field, we focused on observational studies in adult travellers (>16 years). Studies of infection in endemic populations were excluded. Appropriate publications were selected from the abstract list by two authors, with additional relevant articles included from their references. We have reviewed guidelines from the World Health Organization, Centers for Disease Control and Prevention, Public Health England, and the European Society for Clinical Microbiology and Infectious Diseases, and have compiled key recommendations from these. International travel is increasingly common. The United Nations World Tourism Organisation estimates that by 2030, nearly 2 billion people will travel internationally each year, most of them to emerging economies.1 In the UK alone, there were more than 70 million visits abroad by UK residents in 2016, and 37 million overseas residents visiting the UK.2 Illness associated with travel is common (box 1). Most infections are mild or self limiting, however their non-specific presentations make them challenging to distinguish from life threatening infections such as malaria.17 Box 1 ### How common is fever in the returning traveller?RETURN TO TEXT
Intramuscular Administration of Placenta-Derived Stromal Cells Enhances Survival of Rhesus Macaque Monkeys Exposed to Total Body Irradiation
Authors: Noa Sher, Tal Prezma, Dana Fuchs-Telem, Niva Shraga Heled, Simon Authier, Polly Chang, Alexis Ascah, James Bakke, Janet Gahagen, Racheli Ofir
Journal: Blood (2017)
Abstract P166: Multimorbidity and Risk of Mortality in China: Results From the Chinese Electronic Health Records Research in Yinzhou (CHERRY) Study
Authors: Hongbo Lin, Dudan Zhang, Peng Shen, Zhe Xu, Yaqin Si, Xun Tang, Pei Gao
Journal: Circulation (2017)

Introduction: The prevalence of multimorbidity is increasing in developed countries, while corresponding research in Chinese population is limited. Methods: A population-based cohort in Yinzhou located in an eastern coastal area of China (961,008 adults ≥18 years in 2009; latest mortality follow-up: Nov 2015; 22,637 deaths; 6.53 million person-years at risk) was assembled by linking epidemiological surveys, electronic records for chronic disease management, health administrative and medical records databases. Multimorbidity was defined as the presence of two or more following disorders: hypertension, diabetes, cardiovascular disease or cancer. History of selected diseases was extracted from the electronic records for chronic disease management. Follow-up on fatal events is achieved through records linkage to the regional system of death surveillance. Results: Overall age- and sex-standardized prevalence of one, two or ≥3 disorders were 16.16% (16.09% - 16.23%), 4.11% (4.07% - 4.15%) and0.36% (0.35% - 0.38%) respectively, whereas 41.73%, 14.41% and 1.67% were observed in people aged 60 years and older. The all-cause mortality rate adjusted to the age of 60 was 4.77 per 1000 person-years. Comparing to people without any selected diseases, the age- and sexadjusted HRs for all-cause mortality were 1.17 (1.14, 1.21) in those with one disorder, 1.78 (1.72, 1.86) in those with two morbidities, and 2.97 (2.76, 3.19) in those with ≥3 morbidities. The HRs in those with multimorbidites were higher in younger people and were heterogeneous among different combinations of multimorbidites. Population-attributable fractions (PAF) for all-cause mortality due to one, two or ≥3 disorders were 2.63%, 3.04% and 0.67% respectively (1.28%, 7.69% and 2.34% in people aged 60 years and older). Conclusions: The CHERRY study can serve as a valuable big data resource for scientific research in China. Multimorbidity is becoming acommon condition in Chinese population, especially in older population, and is associated with high mortality. A complementary strategy is required for population health interventions.
Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study)
Authors: John R. Bergquist, Harsh N. Shah, Elizabeth B. Habermann, Matthew C. Hernandez, Tommy Ivanics, Michael L. Kendrick, Rory L. Smoot, David M. Nagorney, Mitesh J. Borad, Robert R. McWilliams, Mark J. Truty
Journal: International Journal of Surgery (2018)
Trump promises cheaper drugs and experimental treatments for terminally ill people
Authors: Janice Hopkins Tanne
Journal: BMJ (2018)

In his first State of the Union speech, President Donald Trump was long on cheer but short on details, particularly relating to healthcare.

Unlike his inaugural address a year ago when he referred to the state of poverty, urban decay, poor education, crime, drugs, and a general state of misery in the USA as “American carnage,” this year he said that the nation had made “incredible progress” and that this was “our new American moment.”1

Trump emphasized growth in the economy and employment and tax cuts for the middle class. Some claims were disputed by fact checkers at Politifact , the New York Times , and the Los Angeles Times , among others.2 He also said that his administration had eliminated many regulations and that “we have ended the war on clean coal.”

He …
One-pot synthesis of albumin-gadolinium stabilized polypyrrole nanotheranostic agent for magnetic resonance imaging guided photothermal therapy
Authors: Zhe Yang, Wenshan He, Hongyi Zheng, Jielin Wei, Pei Liu, Wei Zhu, Leping Lin, Li Zhang, Changfeng Yi, Zushun Xu, Jinghua Ren
Journal: Biomaterials (2018)
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study
Authors: Boris Waldman, Jean-Claude Ansquer, David R Sullivan, Alicia J Jenkins, Neil McGill, Luke Buizen, Timothy M E Davis, James D Best, Liping Li, Michael D Feher, Christelle Foucher, Y Antero Kesaniemi, Jeffrey Flack, Michael C d'Emden, Russell S Scott, John Hedley, Val Gebski, Anthony C Keech
Journal: The Lancet Diabetes & Endocrinology (2018)
The p53 gain of function mutation p53 R172H accelerates oral tumor growth, centrosome amplification and aneuploidy
Authors: Sergio Acin, Carlos Caulin
Journal: Cancer Research (2008)

4330   Oral cancer results from the accumulation of genetic alterations. More than 50% of the squamous cell carcinomas (SCC) that develop in the oral cavity carry mutations in the p53 gene. Most of these mutations are missense mutations that result in expression of altered forms of p53, some of which may acquire oncogenic properties.  To determine the role of p53 mutations in oral cancer development we generated mice in which the p53 gain of function mutation p53 R172H  (equivalent to human p53 R175H ) or loss of p53 can be induced in the oral cavity. Tumor initiation in these mice was achieved by co-activation of the K-ras G12D  allele. Using this system we compared the consequences of activating p53 gain and loss of function mutations during oral tumor development. We found that activation of the p53 R172H  allele, but not the p53 loss of function mutation, contributes to oral tumor initiation and accelerates oral tumor growth. To identify molecular mechanisms involved in the oncogenic function of p53 R172H  we compared the expression profiles of oral tumors that developed in mice that carry the p53 R172H  mutation with tumors in which the p53 gene was deleted. Detailed analysis of the expression levels of genes involved in cell cycle determined that cyclin B1 was overexpressed in the p53 R172H  tumors, suggesting that p53 R172H  may accelerate oral tumor growth, at least in part, by inducing the expression of cyclin B1. To characterize in more detail the functional role of mutant p53, we derived cell lines from the mouse oral tumors. Using these cells we demonstrated that p53 R172H  can activate the cyclinB1 promoter and modulate cyclin B1 expression. In addition, we found that oral tumor cells that express p53 R172H  exhibited increased centrosome amplification and aneuploidy compared to cells that do not express p53, suggesting that mutant p53 may accelerate oral tumor progression by promoting genetic instability.  These observations support a gain-of-function role for p53 R172H  in oral cancer development and suggest that mutations in p53 contribute to oral tumor progression by modulating the expression of genes involved in centrosome duplication and genomic instability. We are currently investigating the role of cyclinB1 in p53 R172H  -mediated centrosome amplification and genomic instability during oral cancer development.
Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion
Authors: Robert Zymliński, Jan Biegus, Mateusz Sokolski, Paweł Siwołowski, Sylwia Nawrocka‐Millward, John Todd, Ewa A. Jankowska, Waldemar Banasiak, Gad Cotter, John G. Cleland, Piotr Ponikowski
Journal: European Journal of Heart Failure (2018)
Evaluating Readmission—Need for More Clarity on Methods
Authors: Harlan M. Krumholz, Kumar Dharmarajan, Sharon-Lise T. Normand
Journal: JAMA Cardiology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Reduced D-dimer Levels In C1-esterase-inhibitor Hereditary Angioedema (C1-INH-HAE) Patients Treated With Subcutaneous C1-esterase-inhibitor (C1-INH[SC]): Findings From The COMPACT Study
Authors: Avner Reshef, Marco Cicardi, Bruce L. Zuraw, Timothy Craig, Teresa Caballero, John-Philip Lawo, Iris Jacobs
Journal: Journal of Allergy and Clinical Immunology (2018)
P099 Intensive 24-week physiotherapy programme in patients with idiopathic inflammatory myopathies – preliminary data from a single-centre controlled study
Authors: M Spiritovic, S Oreska, H Storkanova, P Cesak, A Rathouska, K Kubinova, M Klein, L Vernerova, O Ruzickova, H Mann, K Pavelka, L Senolt, J Vencovský, M Tomcik
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Introduction</h3> Presence of muscular inflammation, followed by atrophy in idiopathic inflammatory myopathies (IIM) leads to impaired function, reduced muscle strength, endurance and aerobic capacity, decreasing quality of life. Data on the efficacy of non-pharmacologic care in IIM is very limited due to variety in studied interventions/outcomes. <h3>Objectives</h3> To address the limitations of existing studies, and evaluate the effect of a controlled, long-term (24 week intervention, 24 week follow-up), intensive (1 hour physiotherapy twice weekly, and home-exercise for 1 hour 5x weekly), tailored physiotherapy program to improve muscle strength, endurance and deep stabiliser system, and quality of life/disability in cohorts with a substantial number of IIM patients. <h3>Methods</h3> All patients fulfilled the Bohan and Peter 1975 diagnostic criteria, had muscle involvement, and were consecutively recruited between 2014–2016. At months 0,3,6,12 all patients were assessed by a physician (physical examination, MITAX, MYOACT, and MDI), and a physiotherapist blinded to intervention (MMT-8 – muscle strength test, FI-2 – muscle endurance test), patients filled out patient reported outcomes (PRO)/questionnaires (HAQ, SF-36, Beck's depression inventory-II (BDI-II), PROs assessing nutrition and fatigue), body composition was analysed using densitometry (iDXA Lunar) and bioelectric impedance (BIA2000-M), and patients provided blood for routine laboratory analysis and biobanking. Normality of data was tested and inter-group analysis performed with 2-way ANOVA and intra-group analysis by Friedman's test with Dunn's post hoc test. <h3>Results</h3> 27 IIM patients were recruited into the intervention group (IG) and 27 patients into the control group (CG). Compared to observed statistically significant deterioration in CG over the period of months 0–6, we found statistically significant improvement in FI-2, MMT8, HAQ, BDI-II. Only numerical improvement in IG compared to numerical deterioration in CG, which has not reached statistical significance, was observed in SF-36 and fatigue PROs. <h3>Conclusions</h3> Our physiotherapy program led to a significant improvement in muscle strength, endurance, and function. Additionally, patients expressed a decrease in the level of depression. The improvements were clinically meaningful in a substantial proportion of patients. <h3>Acknowledgements</h3> Supported by AZV-16–33574A. <h3>Disclosure of interest</h3> None declared
Critical role of plasmacytoid dendritic cells in induction of oral tolerance
Authors: Tomofumi Uto, Hideaki Takagi, Tomohiro Fukaya, Junta Nasu, Takehito Fukui, Noriaki Miyanaga, Keiichi Arimura, Takeshi Nakamura, Narantsog Choijookhuu, Yoshitaka Hishikawa, Katsuaki Sato
Journal: Journal of Allergy and Clinical Immunology (2018)
Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer
Authors: Yuan-Chin Tsai, Tao Zeng, Wassim Abou-Kheir, Hsiu-Lien Yeh, Juan Juan Yin, Yi-Chao Lee, Wei-Yu Chen, Yen-Nien Liu
Journal: Molecular Cancer (2018)

ETS variant gene 6 (ETV6) is a putative tumor suppressor and repressed by epidermal growth factor receptor (EGFR) signaling in prostate cancer. Since EGFR antagonists seem ineffective in castration-resistant prostate cancer (CRPC), we aim to study the role of ETV6 in the development of drug resistance. Etv6 target gene was validated by ChIP and promoter reporter assays. Correlation of ETV6 and TWIST1 was analyzed in human clinical datasets and tissue samples. Migration, invasion, and metastasis assays were used to measure the cellular responses after perturbation of ETV6 -TWIST1 axis. Proliferation and tumor growth in xenograft model were performed to evaluate the drug sensitivities of EGFR-tyrosine kinase inhibitors (TKIs). ETV6 inhibits TWIST1 expression and disruption of ETV6 promotes TWIST1-dependent malignant phenotypes. Importantly, ETV6 is required to the anti-proliferation effects of EGFR-TKIs, partly due to the inhibitory function of ETV6 on TWIST1. We also found that EGFR-RAS signaling is tightly controlled by ETV6, supporting its role in TKI sensitivity. Our study demonstrates that disruption of ETV6 contributes to EGFR-TKI resistance, which is likely due to derepression of TWIST1 and activation of EGFR-RAS signaling. Our results implicate ETV6 as a potential marker for predicting efficacy of an EGFR-targeted anticancer approach. Combination treatment of TWIST1 inhibitors could sensitize the anti-proliferation effects of EGFR-TKIs.